
MLYS
Mineralys Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
13.880
Open
13.880
VWAP
--
Vol
3.79K
Mkt Cap
904.63M
Low
13.880
Amount
--
EV/EBITDA(TTM)
--
Total Shares
49.65M
EV
561.61M
EV/OCF(TTM)
--
P/S(TTM)
--
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.750
-23.47%
--
--
-0.734
-35.02%
--
--
-0.739
-11.02%
Estimates Revision
Stock Price
Go Down

-2.32%
In Past 3 Month
7 Analyst Rating

165.56% Upside
Wall Street analysts forecast MLYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLYS is 36.86 USD with a low forecast of 15.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy

165.56% Upside
Current: 13.880

Low
15.00
Averages
36.86
High
48.00

165.56% Upside
Current: 13.880

Low
15.00
Averages
36.86
High
48.00
Jefferies
Hold
initiated
$15
2025-06-10
Reason
Jefferies
Price Target
$15
2025-06-10
initiated
Hold
Reason
Jefferies initiated coverage of Mineralys Therapeutics (MLYS) with a Hold rating and $15 price target. Mineralys has a clinically derisked and novel "$1B-plus blood pressure pill" for which the firm expects the company to file for approval in 2026. Consensus assumes $1B in sales in 2033, but the firm's estimate is about 40%-50% lower due to access and competition from AstraZeneca (AZN). Upside potential can be debated if Mineralys finds a partner to accelerate the launch, but it is "hard to handicap the economics at this point and would take away a near term M/A scenario," the analyst added.
Guggenheim
Seamus Fernandez
Buy
downgrade
$52 -> $48
2025-05-14
Reason
Guggenheim
Seamus Fernandez
Price Target
$52 -> $48
2025-05-14
downgrade
Buy
Reason
Guggenheim analyst Seamus Fernandez lowered the firm's price target on Mineralys Therapeutics to $48 from $52 and keeps a Buy rating on the shares. The firm, which is updating its model after Q1 earnings and catching up with management, says results were "largely incremental," but highlights that Mineralys expects to have a pre-NDA meeting with the FDA in Q4 to ensure the agency and the company are aligned on expectations for the NDA package for lorundrostat.
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Maintains
$30 → $42
2025-04-02
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$30 → $42
2025-04-02
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$30
2025-03-10
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$30
2025-03-10
Reiterates
Strong Buy
Reason
Guggenheim
Seamus Fernandez
Strong Buy
Reiterates
n/a
2025-02-24
Reason
Guggenheim
Seamus Fernandez
Price Target
n/a
2025-02-24
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$30
2025-02-13
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$30
2025-02-13
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Mineralys Therapeutics Inc (MLYS.O) is -4.73, compared to its 5-year average forward P/E of -4.05. For a more detailed relative valuation and DCF analysis to assess Mineralys Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-4.05
Current PE
-4.73
Overvalued PE
-2.83
Undervalued PE
-5.26
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-2.60
Current EV/EBITDA
-3.30
Overvalued EV/EBITDA
-0.15
Undervalued EV/EBITDA
-5.05
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+25.69%
-44.45M
Operating Profit
FY2025Q1
YoY :
+33.97%
-42.21M
Net Income after Tax
FY2025Q1
YoY :
+12.86%
-0.79
EPS - Diluted
FY2025Q1
YoY :
+136.94%
-45.49M
Free Cash Flow
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 232.53% over the last month.
Sold
0-3
Months
891.5K
USD
5
3-6
Months
1.4M
USD
4
6-9
Months
339.3K
USD
3
0-12
Months
352.4K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
4
37.2M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 516.79% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
3.2M
Volume
Months
6-9
2
524.1K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 232.53% over the last month.
Sold
0-3
Months
891.5K
USD
5
3-6
Months
1.4M
USD
4
6-9
Months
339.3K
USD
3
0-12
Months
352.4K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
4
37.2M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MLYS News & Events
Events Timeline
2025-06-30 (ET)
2025-06-30
11:23:11
Mineralys Therapeutics announces publication of Phase 3 Launch-HTN trial results

2025-06-17 (ET)
2025-06-17
07:03:20
Mineralys announces its Phase 2 Explore-CKD trial met primary endpoint

2025-05-26 (ET)
2025-05-26
08:08:00
Mineralys announces late-breaking presentation of data from Launch-HTN trial

Sign Up For More Events
Sign Up For More Events
News
4.0
07-15TipRanks3 Best Stocks to Buy Now, 7/15/2025, According to Top Analysts
9.0
06-30Yahoo FinanceMineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
9.0
06-17BenzingaMineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps
Sign Up For More News
People Also Watch

BWMN
Bowman Consulting Group Ltd
35.160
USD
0.00%

SWBI
Smith & Wesson Brands Inc
8.000
USD
0.00%

AROW
Arrow Financial Corp
27.290
USD
0.00%

KELYA
Kelly Services Inc
12.860
USD
0.00%

ARCT
Arcturus Therapeutics Holdings Inc
13.060
USD
0.00%

TWFG
TWFG Inc
30.080
USD
0.00%

DCTH
Delcath Systems Inc
10.910
USD
0.00%

GCBC
Greene County Bancorp Inc
24.140
USD
0.00%
FAQ

What is Mineralys Therapeutics Inc (MLYS) stock price today?
The current price of MLYS is 13.88 USD — it has increased 0 % in the last trading day.

What is Mineralys Therapeutics Inc (MLYS)'s business?

What is the price predicton of MLYS Stock?

What is Mineralys Therapeutics Inc (MLYS)'s revenue for the last quarter?

What is Mineralys Therapeutics Inc (MLYS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Mineralys Therapeutics Inc (MLYS)'s fundamentals?

How many employees does Mineralys Therapeutics Inc (MLYS). have?
